Cart
0

Pain Management Drugs Market by Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Antimigraine Agents, Antidepressants, Opioids [Tramadol, Hydrocodone, Oxycodone, and Others], and Nonnarcotic Analgesics) and Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, and Fibromyalgia) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Get 20% Free Customization In This Report
LI_17404
Pages: 170
Oct 2017 | 5001 Views
 
Author's : Nikita Chavan and Tenzin Kunsel
Tables: 69
Charts: 31
 

Pain Management Drugs Market Overview:

The Global Pain Management Drugs Market is estimated to reach from $58,577 million in 2016, $77,131 million by 2023. It is anticipated to register a CAGR of 4% during the forecast period, 2017-2023. Pain is a distressing sensory and emotional feeling, which occurs due to tissue damage or illness. In addition, various diseases, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer can cause pain. The duration of pain varies from short term known as acute pain to long term referred as chronic pain. Acute pain is a sudden onset of pain, whereas chronic pain occurs due to aging conditions of bone & joints, nerve damage, or injury. The management of pain involves reduction or treatment of pain using a particular set of drugs. Various drugs are available which provide pain relief through a variety of physiological mechanism, such as by targeting the nociceptors.

Global Pain Management Drugs Market Segmentation

Get more information on this report : Request Sample Pages

The global pain management drugs market is segmented based on drug class, indication, and geography. On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, antimigraine agents, antidepressants, opioids, and nonnarcotic analgesics. Opioids are further classified into tramadol, hydrocodone, oxycodone, and others (opioids include fentanyl, morphine, meperidine, codeine, and methadone). By indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, post-operative pain, migraine, and fibromyalgia. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Drivers, Restraints, and Opportunities

The impact of the driving factors is expected to surpass the effect of restraints. The advancements in drug development and presence of large untapped markets in the developing economies are anticipated to provide new avenues for the industry growth in the near future.

Drivers and Restraints

Get more information on this report : Request Sample Pages

 

Global Pain Management Drugs Market: Key Geographical Segment

North America accounted for the largest share of the global pain management drugs market in 2016. It is expected to maintain its dominance throughout the forecast period.

 

Global Pain Management Drugs Market, by region, 2016 (%)

Get more information on this report : Request Sample Pages

 

The key players operating in the global pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Endo Health Solutions, Inc., Purdue Pharma L.P., Pfizer, Inc., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc.

Other prominent players in the value chain of the pain management drugs market include Allergen Inc., Bayer AG, Bristol-Myers Squibb, Valeant Pharmaceuticals International Inc., Boehringer Ingelheim, Sorrento Therapeutics, WEX Pharmaceuticals, and Zynerba Pharmaceuticals.

 

Key Benefits of the Pain Management Drugs Market Report for Stakeholders:

  • It entails a detailed quantitative analysis of the current market trends to identify the prevailing opportunities, during the period, 2016- 2023.
  • It offers market estimations on the basis of comprehensive analysis of the key developments in the industry.
  • It provides in-depth assessment of the market with respect to drug class, indication, and geography.
  • It enlists the development strategies adopted by key manufacturers to understand the competitive scenario of the market.

Pain Management Drugs Market Key Segments:

By Drug Class

  • NSAIDs
  • Anesthetics
  • Anticonvulsants
  • Antimigraine Agents
  • Antidepressants
  • Opioids
    • Tramadol
    • Hydrocodone
    • Oxycodone
    • Others
  • Nonnarcotic Analgesics

By Indication

  • Arthritic Pain
  • Neuropathic Pain
  • Cancer Pain
  • Chronic Back Pain
  • Postoperative Pain
  • Migraine
  • Fibromyalgia

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

 

 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTER’S FIVE FORCES ANALYSIS
3.4. REGULATION AND REIMBURSEMENT SCENARIO
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Favorable regulatory scenario
3.5.1.2. Increase in geriatric population
3.5.1.3. Rise in incidence of chronic diseases

3.5.2. Restraints

3.5.2.1. Availability of alternative therapies
3.5.2.2. Drug exploitation
3.5.2.3. Patent expiration of prescription drugs

3.5.3. Opportunities

3.5.3.1. Advancements in drug development
3.5.3.2. Untapped markets in developing economies

Chapter: 4 PAIN MANAGEMENT DRUGS MARKET, BY DRUG TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. NSAIDS

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. ANESTHETICS

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. ANTICONVULSANTS

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

4.5. ANTI-MIGRAINE AGENTS

4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast

4.6. ANTIDEPRESSANTS

4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast

4.7. OPIOIDS

4.7.1. Key market trends
4.7.2. Key growth factors and opportunities
4.7.3. Market size and forecast
4.7.4. Tramadol
4.7.5. Hydrocodone
4.7.6. Oxycodaone
4.7.7. Others

4.8. NON-NARCOTIC ANALGESICS

4.8.1. Key market trends
4.8.2. Key growth factors and opportunities
4.8.3. Market size and forecast

Chapter: 5 PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ARTHRITIC PAIN

5.2.1. Market size and forecast

5.3. NEUROPATHIC PAIN

5.3.1. Market size and forecast

5.4. CANCER PAIN

5.4.1. Market size and forecast

5.5. CHRONIC BACK PAIN

5.5.1. Market size and forecast

5.6. POST-OPERATIVE PAIN

5.6.1. Market size and forecast

5.7. MIGRAINE

5.7.1. Market size and forecast

5.8. FIBROMYALGIA

5.8.1. Market size and forecast

Chapter: 6 PAIN MANAGEMENT DRUGS MARKET, BY GEOGRAPHY

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast by country
6.2.4. Market size and forecast by drug class
6.2.5. Market size and forecast by indications

6.2.5.1. U.S. market size and forecast by drug class
6.2.5.2. U.S. market size and forecast by indication
6.2.5.3. Canada market size and forecast by drug class
6.2.5.4. Canada market size and forecast by indication
6.2.5.5. Mexico market size and forecast by drug class
6.2.5.6. Mexico market size and forecast by indication

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast by country
6.3.4. Market size and forecast by drug class
6.3.5. Market size and forecast by indication

6.3.5.1. UK market size and forecast by drug class
6.3.5.2. UK market size and forecast by indication
6.3.5.3. France market size and forecast by drug class
6.3.5.4. France market size and forecast by indication
6.3.5.5. Germany market size and forecast by drug class
6.3.5.6. Germany market size and forecast by indication
6.3.5.7. Italy market size and forecast by drug class
6.3.5.8. Italy market size and forecast by indication
6.3.5.9. Spain market size and forecast by drug class
6.3.5.10. Spain market size and forecast by indication
6.3.5.11. Rest of Europe market size and forecast by drug class
6.3.5.12. Rest of Europe market size and forecast by indication

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast by country
6.4.4. Market size and forecast by drug class
6.4.5. Market size and forecast by indications

6.4.5.1. Japan market size and forecast by drug class
6.4.5.2. Japan market size and forecast by indication
6.4.5.3. China market size and forecast by drug class
6.4.5.4. China market size and forecast by indication
6.4.5.5. Australia market size and forecast by drug class
6.4.5.6. Australia market size and forecast by indication
6.4.5.7. South Korea market size and forecast by drug class
6.4.5.8. South Korea market size and forecast by indication
6.4.5.9. India market size and forecast by drug class
6.4.5.10. India market size and forecast by indication
6.4.5.11. Taiwan market size and forecast by drug class
6.4.5.12. Taiwan market size and forecast by indication
6.4.5.13. Rest of Asia-Pacific market size and forecast by drug class
6.4.5.14. Rest of Asia-Pacific market size and forecast by indication

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast by country
6.5.4. Market size and forecast by drug class
6.5.5. Market size and forecast by indication

6.5.5.1. Brazil market size and forecast by drug class
6.5.5.2. Brazil market size and forecast by indication
6.5.5.3. South Africa market size and forecast by drug class
6.5.5.4. South Africa market size and forecast by indication
6.5.5.5. Saudi Arabia market size and forecast by drug class
6.5.5.6. Saudi Arabia market size and forecast by indication
6.5.5.7. Rest of LAMEA market size and forecast by drug class
6.5.5.8. Rest of LAMEA market size and forecast by indication

Chapter: 7 COMPANY PROFILES

7.1. NOVARTIS AG

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Business performance
7.1.5. Key strategic moves and developments

7.2. ELI LILLY & COMPANY

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key strategic moves and developments

7.3. ABBOTT LABORATORIES, INC.

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.3.5. Key strategic moves and developments

7.4. ENDO HEALTH SOLUTIONS, INC.

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Business performance
7.4.5. Key strategic moves and developments

7.5. PURDUE PHARMA L.P.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.5.5. Key strategic moves and developments

7.6. PFIZER, INC.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Business performance
7.6.5. Key strategic moves and developments

7.7. F. HOFFMANN LA ROCHE LTD.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Business performance
7.7.5. Key strategic moves and developments

7.8. MERCK & CO. INC.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance
7.8.5. Key strategic moves and developments

7.9. JOHNSON & JOHNSON

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Business performance
7.9.5. Key strategic moves and developments

7.10. GLAXOSMITHKLINE PLC.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Business performance
7.10.5. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 2. PAIN MANAGEMENT DRUGS MARKET USING NSAIDS, BY REGION, 2016-2023 ($MILLION)
TABLE 3. PAIN MANAGEMENT DRUGS MARKET USING ANESTHETICS, BY REGION, 2016-2023 ($MILLION)
TABLE 4. PAIN MANAGEMENT DRUGS MARKET USING ANTICONVULSANTS, BY REGION, 2016-2023 ($MILLION)
TABLE 5. PAIN MANAGEMENT DRUGS MARKET USING ANTI-MIGRAINE AGENTS, BY REGION, 2016-2023 ($MILLION)
TABLE 6. PAIN MANAGEMENT DRUGS MARKET USING ANTIDEPRESSANTS, BY REGION, 2016-2023 ($MILLION)
TABLE 7. PAIN MANAGEMENT DRUGS MARKET USING OPIOIDS, BY REGION, 2016-2023 ($MILLION)
TABLE 8. PAIN MANAGEMENT DRUGS MARKET USING NON-NARCOTIC ANALGESICS, BY REGION, 2016-2023 ($MILLION)
TABLE 9. GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 10. PAIN MANAGEMENT DRUGS MARKET FOR ARTHRITIC PAIN, BY REGION, 2016-2023 ($MILLION)
TABLE 11. PAIN MANAGEMENT DRUGS MARKET FOR NEUROPATHIC PAIN, BY REGION, 2016-2023 ($MILLION)
TABLE 12. PAIN MANAGEMENT DRUGS MARKET FOR CANCER PAIN, BY REGION, 2016-2023 ($MILLION)
TABLE 13. PAIN MANAGEMENT DRUGS MARKET FOR CHRONIC BACK PAIN, BY REGION, 2016-2023 ($MILLION)
TABLE 14. PAIN MANAGEMENT DRUGS MARKET FOR POST-OPERATIVE PAIN, BY REGION, 2016-2023 ($MILLION)
TABLE 15. PAIN MANAGEMENT DRUGS MARKET FOR MIGRAINE, BY REGION, 2016-2023 ($MILLION)
TABLE 16. PAIN MANAGEMENT DRUGS MARKET FOR FIBROMYALGIA, BY REGION, 2016-2023 ($MILLION)
TABLE 17. PAIN MANAGEMENT DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 18. NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 19. NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 20. NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 21. U.S. PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 22. U.S. PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 23. CANADA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 24. CANADA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 25. MEXICO PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 26. MEXICO PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 27. EUROPE PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 28. EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 29. EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 30. UK PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 31. UK PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 32. FRANCE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 33. FRANCE PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 34. GERMANY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 35. GERMANY PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 36. ITALY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 37. ITALY PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 38. SPAIN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 39. SPAIN PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 40. REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 41. REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 42. ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 43. ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 44. ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 45. JAPAN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 46. JAPAN PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 47. CHINA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 48. CHINA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 49. AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 50. AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 51. SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 52. SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 53. INDIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 54. INDIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 55. TAIWAN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 56. TAIWAN PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 57. REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 58. REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 59. LAMEA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 60. LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 61. LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 62. BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 63. BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 64. SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 65. SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 66. SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 67. SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 68. REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 69. REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)

LIST OF FIGURES

FIGURE 1. SEGMENTATION OF GLOBAL PAIN MANAGEMENT DRUGS MARKET
FIGURE 2. TOP INVESTMENT POCKETS IN GLOBAL PAIN MANAGEMENT DRUGS MARKET
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 5. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 6. BARGAINING POWER OF BUYERS
FIGURE 7. BARGAINING POWER OF SUPPLIERS
FIGURE 8. THREAT OF NEW ENTRANTS
FIGURE 9. THREAT OF SUBSTITUTION
FIGURE 10. COMPETITIVE RIVALRY
FIGURE 11. RESTRAINTS AND DRIVERS: GLOBAL PAIN MANAGEMENT DRUGS MARKET
FIGURE 12. U.S. PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 13. CANADA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 14. MEXICO PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 15. UK PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 16. FRANCE PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 17. GERMANY PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 18. ITALY PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 19. SPAIN PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 20. REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 21. JAPAN PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 22. CHINA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 23. AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 24. SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 25. INDIA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 26. TAIWAN PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 27. REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 28. BRAZIL PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 29. SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 30. SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 31. REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)

 

Pain management drugs are medications that are used to relive pain. Over the recent years, the demand for pain management drugs is increasing rapidly. Pain can be caused due to various reasons such as chronic diseases, cancer, and surgeries. Rise in use of nonsteroidal anti-inflammatory drugs and opioids for the treatment of various pain conditions is a major driver of the pain management market. Thus, these segments are the largest contributors towards the market growth. Presence of large geriatric population base, rise in global prevalence of cancer, and availability of pipeline drugs that pose to be promising treatment options for patients with chronic diseases further contribute towards the growth of the market. However, patent expiration of the major best-seller drugs such as pregabalin and duloxetine by Pfizer and Eli Lilly & Co., respectively, and availability of alternative therapies such as acupuncture, massage, and medical devices hamper the market growth.

The employment of pain management drugs is highest in North America, owing of increase in adoption of these drugs, high prevalence of chronic diseases, and increase in disposable income among customers. In addition, the presence of a large geriatric population and favorable regulatory & healthcare reforms such as the U.S. Patient Protection and Affordable Care Act of 2010 supplement the market growth. Although the use of pain management drugs in Asia-Pacific and LAMEA is low, the adoption rate is expected to increase owing to rise in disposable income and surge in incidence of chronic disease. China and India are the potential markets in Asia-Pacific. Moreover, increase in R&D investment, upsurge in healthcare expenditure, and rise in government funding & initiatives propel the market growth in Asia-Pacific.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Pain Management Drugs Market- Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $4176
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $4640
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5540
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6654
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $9280
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo